B-intervention	0	14	Pentoxifylline
I-intervention	15	18	and
I-intervention	19	26	vitamin
I-intervention	27	28	E
O	29	38	treatment
O	39	42	for
O	43	53	prevention
O	54	56	of
B-condition	57	66	radiation
I-condition	66	67	-
I-condition	67	74	induced
I-condition	75	79	side
I-condition	79	80	-
I-condition	80	87	effects
O	88	90	in
B-eligibility	91	96	women
I-eligibility	97	101	with
I-eligibility	102	108	breast
I-eligibility	109	115	cancer
O	115	116	:
O	117	118	a
O	119	124	phase
O	125	128	two
O	128	129	,
O	130	136	double
O	136	137	-
O	137	142	blind
O	142	143	,
O	144	151	placebo
O	151	152	-
O	152	162	controlled
O	163	173	randomised
O	174	182	clinical
O	183	188	trial
O	189	190	(
O	190	193	Ptx
O	193	194	-
O	194	195	5
O	195	196	)
O	196	197	.

O	198	199	A
O	200	208	previous
O	209	214	study
O	215	218	has
O	219	224	shown
O	225	229	that
O	230	244	pentoxifylline
O	245	247	in
O	248	259	combination
O	260	264	with
O	265	272	vitamin
O	273	274	E
O	275	278	can
O	279	286	reverse
O	287	296	radiation
O	296	297	-
O	297	304	induced
O	305	313	fibrosis
O	313	314	.

O	315	318	The
O	319	322	aim
O	323	325	of
O	326	329	the
O	330	337	present
O	338	343	study
O	344	346	is
O	347	349	to
O	350	361	investigate
O	362	364	if
O	365	368	the
O	369	373	same
O	374	379	drugs
O	380	385	could
O	386	393	prevent
O	394	403	radiation
O	403	404	-
O	404	411	induced
O	412	416	side
O	416	417	-
O	417	424	effects
O	425	427	in
O	428	433	women
O	434	438	with
O	439	445	breast
O	446	452	cancer
O	452	453	.

O	454	455	A
O	456	466	randomised
O	466	467	,
O	468	475	placebo
O	475	476	-
O	476	486	controlled
O	486	487	,
O	488	494	double
O	494	495	-
O	495	500	blind
O	500	501	,
O	502	510	parallel
O	511	516	group
O	517	522	trial
O	523	526	was
O	527	536	performed
O	536	537	.

O	538	543	Women
O	544	548	with
O	549	555	breast
O	556	562	cancer
O	563	567	were
O	568	575	treated
O	576	579	for
O	580	582	12
O	583	589	months
O	590	594	with
O	595	598	400
O	599	601	mg
O	602	616	pentoxifylline
O	617	618	t
O	618	619	.
O	619	620	i
O	620	621	.
O	621	622	d
O	622	623	.
O	624	626	or
B-control	627	634	placebo
O	634	635	,
O	636	638	in
O	639	650	combination
O	651	655	with
O	656	659	100
O	660	662	mg
O	663	670	vitamin
O	671	672	E
O	673	674	t
O	674	675	.
O	675	676	i
O	676	677	.
O	677	678	d
O	678	679	.
O	679	680	,
O	681	689	starting
O	690	691	1
O	691	692	-
O	692	693	3
O	694	700	months
O	701	706	after
O	707	710	the
O	711	721	completion
O	722	724	of
O	725	737	radiotherapy
O	737	738	.

O	739	742	The
O	743	750	primary
O	751	754	end
O	754	755	-
O	755	760	point
O	761	764	was
B-outcome-Measure	765	772	passive
I-outcome-Measure	773	782	abduction
I-outcome-Measure	783	785	of
I-outcome-Measure	786	789	the
I-outcome-Measure	790	798	shoulder
O	798	799	,
O	800	803	and
O	804	807	the
O	808	817	secondary
O	818	821	end
O	821	822	-
O	822	827	point
O	828	831	was
B-outcome-Measure	832	842	difference
I-outcome-Measure	843	845	in
I-outcome-Measure	846	849	arm
I-outcome-Measure	850	857	volumes
O	857	858	.

O	859	862	The
O	863	868	trial
O	869	871	is
O	872	882	registered
O	883	885	on
O	886	889	the
O	890	896	ISRCTN
O	896	897	.
O	898	901	org
O	902	909	website
O	909	910	,
O	911	917	number
O	918	932	ISRCTN39143623
O	932	933	.

B-total-participants	934	936	83
O	937	945	patients
O	946	950	were
O	951	959	included
O	960	962	in
O	963	966	the
O	967	972	study
O	972	973	;
B-intervention-participants	974	976	42
O	977	979	in
O	980	983	the
O	984	998	pentoxifylline
O	998	999	+
O	999	1006	vitamin
O	1007	1008	E
O	1009	1014	group
O	1015	1018	and
B-control-participants	1019	1021	41
O	1022	1024	in
O	1025	1028	the
O	1029	1036	placebo
O	1036	1037	+
O	1037	1044	vitamin
O	1045	1046	E
O	1047	1052	group
O	1052	1053	.

O	1054	1058	Both
O	1059	1069	treatments
O	1070	1074	were
O	1075	1084	generally
O	1085	1089	well
O	1090	1099	tolerated
O	1099	1100	.

O	1101	1106	Seven
O	1107	1115	patients
O	1116	1120	were
B-outcome	1121	1130	withdrawn
I-outcome	1131	1135	from
I-outcome	1136	1139	the
I-outcome	1140	1149	treatment
I-outcome	1150	1153	due
I-outcome	1154	1156	to
I-outcome	1157	1164	disease
I-outcome	1165	1176	progression
O	1176	1177	;
B-iv-bin-abs	1178	1182	four
O	1183	1185	in
O	1186	1189	the
O	1190	1204	pentoxifylline
O	1205	1210	group
O	1211	1214	and
B-cv-bin-abs	1215	1220	three
O	1221	1223	in
O	1224	1227	the
O	1228	1235	placebo
O	1236	1241	group
O	1241	1242	.

O	1243	1245	At
O	1246	1255	inclusion
O	1255	1256	,
O	1257	1265	patients
O	1266	1269	had
B-outcome	1270	1278	impaired
I-outcome	1279	1286	passive
I-outcome	1287	1296	abduction
I-outcome	1297	1299	of
I-outcome	1300	1303	the
I-outcome	1304	1312	shoulder
O	1312	1313	.

O	1314	1320	During
O	1321	1330	treatment
O	1330	1331	,
O	1332	1336	both
O	1337	1340	the
O	1341	1347	groups
O	1348	1356	improved
O	1357	1370	significantly
O	1370	1371	.

B-outcome	1372	1378	Median
I-outcome	1379	1390	improvement
O	1391	1395	from
O	1396	1404	baseline
O	1405	1408	was
B-iv-cont-median	1409	1410	3
I-iv-cont-median	1410	1411	.
I-iv-cont-median	1411	1412	7
I-iv-cont-median	1413	1420	degrees
O	1421	1422	(
O	1422	1423	p
O	1423	1424	=
O	1424	1425	0
O	1425	1426	.
O	1426	1430	0035
O	1430	1431	)
O	1432	1434	on
O	1435	1449	pentoxifylline
O	1450	1453	and
O	1454	1457	was
B-cv-cont-median	1458	1459	9
I-cv-cont-median	1459	1460	.
I-cv-cont-median	1460	1461	4
I-cv-cont-median	1462	1469	degrees
O	1470	1471	(
O	1471	1472	p
O	1472	1473	=
O	1473	1474	0
O	1474	1475	.
O	1475	1479	0041
O	1479	1480	)
O	1481	1483	in
O	1484	1487	the
O	1488	1495	placebo
O	1496	1501	group
O	1501	1502	,
O	1503	1506	but
O	1507	1509	no
O	1510	1520	difference
O	1521	1528	between
O	1529	1532	the
O	1533	1539	groups
O	1540	1543	was
O	1544	1552	detected
O	1553	1554	(
O	1554	1555	p
O	1555	1556	=
O	1556	1557	0
O	1557	1558	.
O	1558	1560	20
O	1560	1561	)
O	1561	1562	.

B-outcome	1563	1566	Arm
I-outcome	1567	1574	volumes
O	1575	1584	increased
O	1585	1589	over
O	1590	1594	time
O	1595	1597	in
O	1598	1601	the
O	1602	1609	placebo
O	1610	1615	group
O	1616	1617	(
B-iv-cont-median	1617	1618	1
I-iv-cont-median	1618	1619	.
I-iv-cont-median	1619	1621	04
I-iv-cont-median	1621	1622	%
O	1622	1623	)
O	1623	1624	,
O	1625	1628	but
O	1629	1632	not
O	1633	1635	on
O	1636	1650	pentoxifylline
O	1651	1652	(
B-cv-cont-median	1652	1653	0
I-cv-cont-median	1653	1654	.
I-cv-cont-median	1654	1656	50
I-cv-cont-median	1656	1657	%
O	1657	1658	)
O	1658	1659	,
O	1660	1663	and
O	1664	1672	differed
O	1673	1686	significantly
O	1687	1694	between
O	1695	1698	the
O	1699	1705	groups
O	1706	1707	(
O	1707	1708	p
O	1708	1709	=
O	1709	1710	0
O	1710	1711	.
O	1711	1715	0172
O	1715	1716	)
O	1716	1717	.

O	1718	1721	The
O	1722	1733	combination
O	1734	1736	of
O	1737	1751	pentoxifylline
O	1752	1755	and
O	1756	1763	vitamin
O	1764	1765	E
O	1766	1769	was
O	1770	1774	safe
O	1775	1778	and
O	1779	1782	may
O	1783	1785	be
O	1786	1790	used
O	1791	1794	for
O	1795	1798	the
O	1799	1809	prevention
O	1810	1812	of
O	1813	1817	some
O	1818	1827	radiation
O	1827	1828	-
O	1828	1835	induced
O	1836	1840	side
O	1840	1841	-
O	1841	1848	effects
O	1848	1849	.
